<<Can someone name we one biotech stock that reacted the way that LGND has done today?>>
Well, TD, my short answer is, "No, I can't." But my longer answer involves GLFD, Guilford Pharmaceuticals. About 6 weeks ago, GLFD signed a *huge* deal for its neuroimmunophilin program. (This is a *very* promissing technology, potentially capable of protecting / regenerating brain cells. Applications for head trauma, Parkinson's, Alzheimers, etc. Dramatic results in rat studies.) Anyway, the "total value" of the deal was twice(!) today's LGND deal's total value. GLFD popped on the news, but is now trading at 27, not substantially higher than it was before the deal was announced. And, GLFD's deal was entirely unrumored and unexpected.
So, it is fair to say that these deals do not always drive stock prices. In the end, it will depend on positive clinicals, and ultimately on revenue generated. In my estimation, everything still looks excellent for LGND, and I am most emphatically not selling. If I can free up some extra cash, I will buy more.
Good luck,
RB |
